7ERA

Crystal structure of human Biliverdin IX-beta reductase B with Olsalazine Sodium (OSS)

Summary for 7ERA

Entry DOI	10.2210/pdb7era/pdb
Descriptor	Flavin reductase (NADPH), NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE, 5-[(E)-(3-carboxy-4-oxidanyl-phenyl)diazenyl]-2-oxidanyl-benzoic acid, ... (5 entities in total)
Functional Keywords	platelets, biliverdin reductase b, blvrb, inhibitors, nadp, olsalazine sodium, oxidoreductase
Biological source	Homo sapiens (Human)
Total number of polymer chains	2
Total formula weight	47240.65
Authors	Griesinger, C.,Lee, D.,Ryu, K.S.,Kim, M.,Ha, J.H. (deposition date: 2021-05-06, release date: 2022-01-19, Last modification date: 2023-11-29)
Primary citation	Kim, M.,Ha, J.H.,Choi, J.,Kim, B.R.,Gapsys, V.,Lee, K.O.,Jee, J.G.,Chakrabarti, K.S.,de Groot, B.L.,Griesinger, C.,Ryu, K.S.,Lee, D. Repositioning Food and Drug Administration-Approved Drugs for Inhibiting Biliverdin IX beta Reductase B as a Novel Thrombocytopenia Therapeutic Target. J.Med.Chem., 65:2548-2557, 2022 Cited by PubMed: 34957824 DOI: 10.1021/acs.jmedchem.1c01664 PDB entries with the same primary citation
Experimental method	X-RAY DIFFRACTION (1.35 Å)

Structure validation